Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Change in Receivables (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Change in Receivables for 4 consecutive years, with $28.0 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 56.14% to $28.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $82.5 million through Dec 2025, up 74.78% year-over-year, with the annual reading at $82.5 million for FY2025, 74.78% up from the prior year.
  • Change in Receivables hit $28.0 million in Q4 2025 for Axsome Therapeutics, up from -$2.3 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $37.4 million in Q2 2025 to a low of -$2.3 million in Q3 2025.
  • Historically, Change in Receivables has averaged $14.9 million across 4 years, with a median of $16.9 million in 2022.
  • Biggest YoY gain for Change in Receivables was 193.21% in 2025; the steepest drop was 161.75% in 2025.
  • Year by year, Change in Receivables stood at $17.4 million in 2022, then fell by 5.7% to $16.4 million in 2023, then rose by 9.14% to $17.9 million in 2024, then soared by 56.14% to $28.0 million in 2025.
  • Business Quant data shows Change in Receivables for AXSM at $28.0 million in Q4 2025, -$2.3 million in Q3 2025, and $37.4 million in Q2 2025.